Nocturia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 13 PAGES: 31

More Info
									                               Nocturia – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1998IDB
                                                                                              Publication Date: April 2012




Nocturia – Pipeline Review, H1 2012                                                           GMDHC1998IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Nocturia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Nocturia Overview .............................................................................................................................................................................. 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Nocturia .............................................................................................................................. 7
Nocturia Therapeutics under Development by Companies ................................................................................................................ 9
Late Stage Products ......................................................................................................................................................................... 10
    Comparative Analysis .................................................................................................................................................................. 10
Mid Clinical Stage Products.............................................................................................................................................................. 11
    Comparative Analysis .................................................................................................................................................................. 11
Early Clinical Stage Products ........................................................................................................................................................... 12
    Comparative Analysis .................................................................................................................................................................. 12
Nocturia Therapeutics – Products under Development by Companies ............................................................................................ 13
Companies Involved in Nocturia Therapeutics Development ........................................................................................................... 14
    Allergan, Inc................................................................................................................................................................................. 14
    Astellas Pharma Inc..................................................................................................................................................................... 15
    Urigen Pharmaceuticals, Inc. ....................................................................................................................................................... 16
    Vantia Therapeutics..................................................................................................................................................................... 17
Nocturia – Therapeutics Assessment ............................................................................................................................................... 18
    Assessment by Monotherapy Products ....................................................................................................................................... 18
    Assessment by Route of Administration ...................................................................................................................................... 19
    Assessment by Molecule Type .................................................................................................................................................... 21
Drug Profiles..................................................................................................................................................................................... 23
    ASP7035 - Drug Profile ............................................................................................................................................................... 23
         Product Description................................................................................................................................................................. 23
         Mechanism of Action ............................................................................................................................................................... 23
         R&D Progress ......................................................................................................................................................................... 23
    URG301 - Drug Profile ................................................................................................................................................................ 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    SER120 - Drug Profile ................................................................................................................................................................. 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    VA106483 - Drug Profile .............................................................................................................................................................. 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ..................................................................................................................
								
To top